
Lantern Pharma Receives FDA Rare Pediatric Disease Designations for LP-184 in Ultra-Rare Children’s Cancers
Lantern Pharma Inc. (NASDAQ: LTRN), an AI-driven biotech company focused on developing targeted cancer therapies through its proprietary RADR® AI and machine learning platform, announced that the FDA has granted it three Rare Pediatric Disease Designations (RPDD). These designations cover…











